Printer Friendly

CURAXIN RECEIVES NOTICE OF PATENT ALLOWANCE.

Cleveland BioLabs, Inc. and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, have received a Notice of Allowance from the U.S. Patent and Trademark Office for the Curaxin U.S. Patent Application Number 12/993,018, titled "Inducing Cell Death by Inhibiting Adaptive Heat Shock Response." This patent was recently issued in the Russian Federation, as well. Curaxins include CBL0137, which is a carbazole and CBL0102, which is a quinacrine.

The European Patent Office also issued a Notice of Grant for European Patent Number EP2356093, titled "Carbazole Compounds and Therapeutic Uses of the Compounds." This patent was also allowed in New Zealand, South Africa, and Kazhakstan.

In addition, the Australian patent authority had previously granted patent Number 2005267117 titled, "Inhibition of NF- kappaB" for carbazole compounds.

Andrei Gudkov, Ph.D., D.Sci., Chief Scientific Officer of Cleveland BioLabs, noted, "Inhibition of adaptive heat shock response and NF-kappaB have long been recognized as attractive targets for oncology therapeutics. In fact, many known efficacious drugs being used today focus on these targets independently, which underscores the importance of these patents. The uniqueness of our Curaxin drug candidates CBL0137 and CBL0102 is that they simultaneously affect both of these pathways and others through interaction with an upstream regulator. As such, we hope our Curaxins will provide a clinically relevant improvement to existing therapies."

CBLI and Incuron recently received a Notice of Allowance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for CBL0137.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. For more information, visit www.cbiolabs.com.

About Incuron, LLC

Incuron, LLC is a Russian Federation based joint venture founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Incuron is developing CBL0102 and CBL0137 for oncology and orphan indications.

For more information, visit http://www.incuron.com.
COPYRIGHT 2013 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Date:Jun 1, 2013
Words:395
Previous Article:AMERICAN CRYOSTEM COLLABORATES WITH RUTGERS UNIV.
Next Article:OCULUS ENTERS INTO TWO KEY AGREEMENTS WITH RUTHIGEN.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |